Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 627-633

  Kreidy, R ^a   Irani Hakime, N ^a  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

Author keywords

Factor V Leiden; Genetics; MTHFR C677T; Prothrombin G20210A; Risk factors; Venous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); VITAMIN K GROUP;

ADULT; AGED; ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; HUMAN; LEBANON; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCREENING; THROMBOPHILIA; AGE; ASIAN; DRUG ANTAGONISM; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; LEG; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MUTATION; NEOPLASM; OBESITY; RECURRENT DISEASE; RISK ASSESSMENT; SURGERY; TREATMENT OUTCOME; VASCULARIZATION; VEIN THROMBOSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LEBANON; LOWER EXTREMITY; MALE; MASS SCREENING; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; NEOPLASMS; OBESITY; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOSIS; VITAMIN K; YOUNG ADULT;

EID: 70350508522     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938.
2. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17(4):259-270.
3. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost. 1996;76(5):651-662.
4. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemost. 1996;76(6):824-834.
5. Rosendaal FR. Venous thrombosis: a multi causal disease. Lancet. 1999;353(9159):1167-1173.
6. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222-1231.
7. Samama MM, Conard J, Toulemonde F. Coagulation abnormalities predisposing to the development of deep vein thrombosis. In: Bergqvist DCA, Nicolaides A, Scurr J, editors. Prevention of Venous Thromboembolism. London: Med-Orion; 1994. p. 43-56.
8. Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease annotation. Br J Haematol. 2000;109(4):699-703.
9. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. Prevalence of factor V R506Q - Leiden among apparently Lebanese patients. J Hematol. 2000;65(1):45-49.
10. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case control study. Arch Intern Med. 2000;160(6):809-815.
11. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82(2):610-619.
12. Kearon C, Salzman EW, Hirsh J. Epidemiology, pathogeneses and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, et al. editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia, PA: JB Lippincott; 2001. p. 1153-1177.
13. Heit JA, O' Fallon, WM, Petterson TM, et al. Relative impact of risk factors of deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11): 1245-1248.
14. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):116-119.
15. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94(4):750-759.
16. Geerts WH, Heit JA, Clagett JP, et al. Prevention of venous thromboembolism. Chest. 2001;119(1 Suppl):S132-S175.
17. Pandoni P. Cancer and thromboembolic disease: how important is the risk of thrombosis? Cancer Treat Rev. 2002;28(3):133-136.
18. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291.
19. Reas DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133-1134.
20. Sabbagh AS, Mahfoud Z, Taher A, Zaatari G, Daher R, Mahfouz RAR. High prevalence of MTHFR gene A 1298 C polymorphism in Lebanon. Genet Test. 2008;12(1):75-80.
21. Zheng YZ, Tong J, Do X, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol. 2000;109(4):870-874.
22. Naushad S, Jamal NJ, Angalena R, Prasad CK, Deva AR. Hyperhomocysteinemia and the compound heterozygous state for methylenetetrahydrofolate reductase are independent risk factors for deep vein thrombosis among South Indians. Blood Coagul Fibrinolysis. 2007;18(2):113-117.
23. Balta G, Gürgey A. Methylenetetrahydrofolate reductase (MTHFR) C677T mutation in Turkish patients with thrombosis. Turk J Pediatr. 1999;41(2):197-199.
24. Zalavras ChG, Giotopoulous S, Dokou E, et al. Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int Angiol. 2002;21(3):2680-2671.
25. Almawi WY, Tamim H, Kreidy R, et al. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis. 2005;19(3): 189-196.
26. Sabbagh AS, Ibrahim G, Kanaan Z, et al. Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridization strip assay approach. Mol Biol Rep. 2009;36(2): 399-403.
27. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10): 3698-3703.
28. Bouaziz-Borgi L, Almawi WY, Mtiraoui N, et al. Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep vein thrombosis in Tunisia and Lebanon. Am J Hematol. 2006;81(8): 641-643.
29. Passam F, Krilis S. Laboratory tests for anti-phospholipid syndrome. Pathology. 2004;36(2):129-138.
30. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001;1:7-26.
31. Gil RJ, Pérez AM, Arias JB, Pascual FB, Romero ES. Agenesis of the inferior vena cava associated with lower extremities and pelvic venous thrombosis. J Vasc Surg. 2006;44(5):1114-1116.
32. Lane DA. Congenital hypoplasia of the inferior vena cava: an under-appreciated cause of deep vein thrombosis among young adults. Mil Med. 2005;170(9):379-342.
33. Chee YL, Culligan DJ, Watson HG. Inferior vena cava malformation as a risk factor for deep vein thrombosis in the young. Br J Haematol. 2001;114(4):878-880.
34. Garcia-Fuster MJ, Forner MJ, Flor-Lorente B, Soler J, Campos S. Inferior vena cava malformations and deep vein thrombosis. Rev Esp Cardiol. 2006;59(2):171-175.
35. Yun SS, Kim JI, Kim KH, Sung GY, Lee DS, Kim JS. Deep vein thrombosis caused by congenital absence of inferior vena cava combined with hyperhomocysteinemia. Ann Vasc Surg. 2004;18(1): 124-129.
36. Parma M, Belotti D, Marinoni S, Pogliani EM. Congenital absence of the inferior vena cava and genetic coagulation abnormalities: a rare associated risk for factor for recurrent idiopathic deep vein thrombosis. Clin Appl Thromb Hemost. 2003;9(4):347-348.
37. Schneider JG, Eynatten MV, Dugi KA, Duex M, Nawroth PP. Recurrent deep venous thrombosis caused by congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation. J Intern Med. 2002;252(3):276-280.
38. Sirlak M, Cakici M, Inan MB, et al. Coexistence of left sided inferior vena cava, deep vein thrombosis of the upper and lower extremities and prothrombotic polymorphisms in a young patient: a case report. Blood Coagul Fibrinolysis. 2008;19(5):443-445.
39. Vidra T, Szomor A, Battyáni I, Mühl D, Losonczy H. [Agenesis of inferior vena cava combined with multiple genetic predisposition in the case of deep venous thrombosis in a young male]. Orv Hetil. 2003;144(46):2283-2286.
40. Bianchi M, Giannini D, Balbarini A, Castiglioni MG. Congenital hypoplasia of the inferior vena cava and inherited thrombophilia: rare associated risk factors for idiopathic deep vein thrombosis. A case report. J Cardiovasc Med (Hagerstown). 2008;9(1):101-104.
41. Zimmermann A, Dirrigl A, Heider P, Metz S, Eckstein HH. [Thrombosis of the inferior vena cava and the iliac and femoral veins in a 24-year old man]. Dtsch Med Wochenschr. 2007;132(1-2):21-24.
42. Fass G, Nasroolah D, Cavenaile JC. Deep vein thrombosis caused by congenital malformation of the inferior vena cava and heterozygous factor V Leiden presenting as venous claudication. Clin Appl Thromb Hemost. 2008;2(Epub ahead of print).
43. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombin mutations and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.
44. Legnani C, Cosmi B, Valdre L, et al. Venous thromboembolism, oral contraceptives and high thrombin levels. J Thromb Haemost. 2003;1(1):112-117.
45. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90(5): 1747-1750.
46. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453-1457.
47. Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002;22(6):1012-1017.
48. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002;116(4):851-854.
49. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low molecular weight heparin in special populations. Pharmacotherapy. 2001;21(2):218-231.
50. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and postthrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4): 632-637.
51. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002; 87(5):791-795.
52. De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med. 2003;3(1):47-60.
53. Bates SM. Management of pregnant women with thrombophilia or a history of venous thromboembolism. ASH Education Book. 2007; 143-150.
54. Normittag R, Pabinger I. Thrombophilia and pregnancy complications. Hamostaseologie. 2006;26(1):59-62.
55. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10(11):1-110.
56. Gajic O, Warner DO, Decker PA, Rana R, Bourke DL, Sprung J. Long-haul air travel before major surgery: a prescription for thromboembolism. Mayo Clin Proc. 2005;80(6):728-731.
57. Parsi KA, McGrath MA, Lord RS. Traveller's venous thromboembolism. Cardiovasc Surg. 2001;9(2):157-158.
58. Spiezia L, Tormene D, Pesavento R, Salmaso L, Simioni P, Prandoni P. Thrombophilia as a predictor of persistent residual vein thrombosis. Hematologica. 2008;93(3):479-480.